Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Learn more about how myelin springs back in the brain after a marathon and how these findings could help people with multiple ...

Quantum BioPharma (NASDAQ: QNTM) has announced that its licensee, Celly Nutrition Corporation, is launching the alcohol-mitigating beverage unbuzzdT ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 ...